57860-45-4

Basic information

• Product Name: p-tolylsulfanyl-acetaldehyde dimethylacetal
• Synonyms: p-tolylsulfanyl-acetaldehyde dimethylacetal
• CAS NO: 57860-45-4
• Molecular Weight: 212.313
• Mol File: 57860-45-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: p-tolylsulfanyl-acetaldehyde dimethylacetal(CAS DataBase Reference)
• NIST Chemistry Reference: p-tolylsulfanyl-acetaldehyde dimethylacetal(57860-45-4)
• EPA Substance Registry System: p-tolylsulfanyl-acetaldehyde dimethylacetal(57860-45-4)

Safety Data

• Hazardous Substances Data: 57860-45-4(Hazardous Substances Data)

Usage

Description

p-tolylsulfanyl-acetaldehyde dimethylacetal, with the molecular formula C11H16OS2, is a colorless liquid characterized by a pungent odor. It is a sulfide and belongs to the class of organic compounds known as dialkyl ethers. p-tolylsulfanyl-acetaldehyde dimethylacetal is synthesized by reacting p-tolylsulfanyl-acetaldehyde with methanol in the presence of an acid catalyst, making it a valuable intermediate in the production of various compounds.

Uses

Used in Fragrance Industry:
p-tolylsulfanyl-acetaldehyde dimethylacetal is used as a fragrance ingredient for its distinct and pungent odor, contributing to the scent profiles of perfumes and personal care products.
Used in Organic Synthesis:
p-tolylsulfanyl-acetaldehyde dimethylacetal is used as a reagent in organic synthesis for the formation of carbon-carbon and carbon-sulfur bonds in various chemical reactions, showcasing its versatility in creating different compound structures.
Used in Pharmaceutical Industry:
p-tolylsulfanyl-acetaldehyde dimethylacetal is used as a valuable intermediate in the pharmaceutical industry for the production of various compounds, highlighting its importance in drug development and synthesis.
Used in Agrochemical Industry:
p-tolylsulfanyl-acetaldehyde dimethylacetal is also utilized in the agrochemical industry, where it serves as an intermediate in the synthesis of compounds used in agriculture for various purposes, such as pest control and crop protection.

Upstream product

• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 106-45-6 para-thiocresol 
• 97-97-2 chloroacetaldehyde dimethyl acetal 

Downstream Products

• 93734-73-7 p-tolylsulfanyl-acetaldehyde-(2,4-dinitro-phenylhydrazone) 
• 14315-14-1 5-methylthianaphthene 

Relevant articles and documents

Antitumor agents. 284. new desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents

We previously reported that the biological acti-vity of analogues of desmosdumotin B (1) was dramatically changed depending on the B-ring system. A naphthalene B-ring analogue 3 exerted potent in vitro activity against a diverse panel of human tumor cell lines with GI50 values of 0.8-2.1 μM. In contrast, 1 analogues with a phenyl B-ring showed unique selective activity against P-glycoprotein (P-gp) overexpressing multidrug resistant cell line. We have now prepared and evaluated 1 analogues with bicyclic or tricyclic aromatic B-ring systems as in vitro inhibitors of human cancer cell line proliferation. Among all synthesized derivatives, 21 with a benzo[b]thiophenyl B-ring was highly active, with GI50 values of 0.06-0.16 μM, and this activity was not influenced by overexpression of P-gp. Furthermore, 21 inhibited tubulin assembly in vitro with an IC50 value of 2.0 μM and colchicine binding by 78% as well as cellular microtubule polymerization and spindle formation.

SUBSTITUTED SULFONIC ACID N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.